Loading…
Entera Bio Ltd. is projected to decline to $1.13 by 2027, a -5% move from its current price of $1.19. ENTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.14 | $1.19 | $1.24 | 0.00% |
| May 30 | $1.12 | $1.19 | $1.26 | -0.01% |
| May 31 | $1.11 | $1.19 | $1.28 | -0.01% |
| Jun 1 | $1.09 | $1.19 | $1.29 | -0.02% |
| Jun 2 | $1.08 | $1.19 | $1.31 | -0.02% |
| Jun 3 | $1.07 | $1.19 | $1.32 | -0.03% |
| Jun 4 | $1.06 | $1.19 | $1.33 | -0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.06 | $1.19 | $1.33 | -0.03% |
| Week 2 | $1.02 | $1.19 | $1.39 | -0.07% |
| Week 3 | $0.9812 | $1.19 | $1.44 | -0.10% |
| Week 4 | $0.9522 | $1.19 | $1.48 | -0.14% |
| Week 5 | $0.9273 | $1.19 | $1.52 | -0.17% |
| Week 6 | $0.9053 | $1.19 | $1.56 | -0.21% |
| Week 7 | $0.8855 | $1.19 | $1.59 | -0.24% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Entera Bio Ltd. is a healthcare company focused on developing oral peptides and protein replacement therapies, with activities in Israel and internationally. It is described as a clinical stage company that develops EB613, an oral teriparatide, which completed the Phase II clinical trial for osteoporosis and Phase I for stress fractures.
The company is also developing EB612, EB618, and GLP-2 programs, with EB612 in Phase I for hypoparathyroidism, EB618 in Phase I for obesity/metabolic and fibrotic disorders, and GLP-2 in Phase I for short bowel syndrome and related mucosal disorders. It has a collaboration with OPKO Biologics, Inc for LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.
Entera Bio Ltd. (ENTX) is a healthcare stock with a current price of $1.24, a market cap of $61.04M, and a rank of 4499.
A major floor 20.2% below — a decisive break under it would weaken the trend.
The nearest floor, 7.6% below — buyers have tended to step in here.
The nearest ceiling, 15.1% above — a clean break opens room to run.
A major ceiling 37.8% above — clearing it would confirm fresh momentum.
Key ENTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ENTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.23 | Sell | $1.22 | Sell |
| MA 10 | $1.25 | Sell | $1.23 | Sell |
| MA 20 | $1.23 | Sell | $1.23 | Sell |
| MA 50 | $1.19 | Sell | $1.25 | Sell |
| MA 100 | $1.33 | Sell | $1.39 | Sell |
| MA 200 | $1.76 | Sell | $1.59 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.12 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -43.58 | Neutral |
| Williams %R (14) | -90.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -8.46 | Sell |
| Bollinger %B (20,2) | 0.37 | Neutral |
| Stochastic %K (14) | 10.00 | Buy |
| TRIX (15) | 0.19 | Buy |
| Awesome (5,34) | 0.02 | Buy |
| Ultimate (7,14,28) | 39.27 | Neutral |
| Momentum (10) | -0.06 | Sell |
| Aroon Osc (25) | 16.00 | Buy |
| Hull MA (9) | 1.21 | Sell |
| ADX (14) | 6.87 | Neutral |
| ATR (14) | 0.05 | Info |
The 30-day technical picture is bullish. RSI14 is 50, SMA50 is $1.20, and SMA200 is $1.76, with a defined support at $1.10 and resistance at $1.37. The 30-day range runs from $0.9267 to $1.66, and the annualized volatility is 80%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.00 | $1.19 | $1.59 | 0% | Neutral | |
| $0.8497 | $1.13 | $1.62 | -5% | Neutral | |
| $0.7782 | $1.08 | $1.63 | -9% | Neutral | |
| $0.7812 | $1.13 | $1.76 | -5% | Neutral | |
| $0.7657 | $1.14 | $1.85 | -4% | Neutral | |
| $1.01 | $1.55 | $2.58 | +30% | Bullish | |
| $1.09 | $1.73 | $2.95 | +45% | Bullish | |
| $0.9593 | $1.57 | $2.74 | +32% | Bullish | |
| $1.06 | $1.77 | $3.16 | +49% | Bullish | |
| $0.9906 | $1.71 | $3.11 | +43% | Bullish | |
| $1.36 | $2.66 | $5.25 | +123% | Bullish | |
| $1.72 | $3.83 | $8.49 | +222% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.00 | $1.19 | $1.40 | +0.00% |
| June 2026 | $0.9712 | $1.15 | $1.41 | -3.03% |
| July 2026 | $0.9841 | $1.18 | $1.48 | +2.67% |
| August 2026 | $0.9861 | $1.20 | $1.52 | +1.24% |
| September 2026 | $0.9395 | $1.15 | $1.48 | -3.91% |
| October 2026 | $0.9299 | $1.15 | $1.49 | -0.24% |
| November 2026 | $0.9673 | $1.20 | $1.58 | +4.74% |
| December 2026 | $0.9596 | $1.20 | $1.59 | -0.13% |
Click any year to see its month-by-month ENTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ENTX to range from $1.00 to $1.59 through 2026. The $1.19 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The ENTX price prediction for 2027 points to an average of $1.13 (low $0.8497, high $1.62) — a potential decline of -5% on today's $1.19. A consolidation phase looks the most probable path here.
In 2028, ENTX is projected to trade between $0.7782 and $1.63, averaging $1.08 — a potential decline of -9% from today's $1.19. That is -4% versus the projected 2027 average. Price action looks broadly range-bound.
Entera Bio Ltd.'s 2029 outlook centres on $1.13, within a $0.7812 to $1.76 range. That is up +4% on the projected 2028 average. That marks a -5% change versus current levels. A consolidation phase looks the most probable path here.
By 2030, ENTX could reach as high as $1.85, with a base case around $1.14 and support toward $0.7657 — roughly -4% from $1.19. Price action looks broadly range-bound.
Expect ENTX to range from $1.01 to $2.58 through 2031. The $1.55 average target implies a +30% move from current prices. That is up +36% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The ENTX price prediction for 2032 points to an average of $1.73 (low $1.09, high $2.95) — a potential gain of +45% on today's $1.19. Momentum favours further upside here.
In 2033, ENTX is projected to trade between $0.9593 and $2.74, averaging $1.57 — a potential gain of +32% from today's $1.19. That is -9% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
Entera Bio Ltd.'s 2034 outlook centres on $1.77, within a $1.06 to $3.16 range. That is up +13% on the projected 2033 average. That marks a +49% change versus current levels. Momentum favours further upside here.
By 2035, ENTX could reach as high as $3.11, with a base case around $1.71 and support toward $0.9906 — roughly +43% from $1.19. Buyers look set to stay in control over this stretch.
Expect ENTX to range from $1.36 to $5.25 through 2040. The $2.66 average target implies a +123% move from current prices. That is up +56% on the projected 2035 average. Momentum favours further upside here.
The ENTX price prediction for 2050 points to an average of $3.83 (low $1.72, high $8.49) — a potential gain of +222% on today's $1.19. Buyers look set to stay in control over this stretch.
Investing $1,000 in ENTX today (≈ 840.336134 ENTX) could be worth
$3,216.89
+$2,216.89 (+222%) by 2050 · US Dollar
Based on the average projected ENTX price of $3.83 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ENTXwould be worth at today's price.
$1,000 invested in ENTX on May 27, 2025 (≈ 537.634404 ENTX) would be worth
$639.78
-$360.22 (-36.0%) today · 0.64× · US Dollar
Based on a ENTX entry price of $1.86 vs. today's $1.19.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.24 | $959.68 | -4.0% |
| 1 month ago | $1.15 | $1,034.78 | +3.5% |
| 3 months ago | $1.51 | $788.08 | -21.2% |
| 6 months ago | $2.38 | $500 | -50.0% |
| 1 year ago | $1.86 | $639.78 | -36.0% |
| All time (5.0y) ago | $3.25 | $366.15 | -63.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ENTX forecast.
Our base-case forecast reaches $2.40 around 2040.
Implied market cap at $2.40: $118.14M
The multi-year forecast shows a neutral stance through 2026, turning bullish from 2031 onward. In 2030 the forecast lists a min of $0.8355, an avg of $1.27, and a max of $2.09 with a ROI of 2.3 and neutral sentiment. The trajectory continues with 2031 min $1.11, avg $1.75, max $2.96 (ROI 40.8, bullish); 2032 min $1.18, avg $1.91, max $3.32 (ROI 54, bullish); 2033 min $1.04, avg $1.74, max $3.09 (ROI 39.9, bullish); 2034 min $1.15, avg $1.98, max $3.61 (ROI 60, bullish); 2035 min $1.06, avg $1.88, max $3.50 (ROI 51.9, bullish).
By 2040 the forecast shows min $1.51, avg $3.05, max $6.17 (ROI 146.1, bullish); and in 2050 min $1.97, avg $4.38, max $9.98 (ROI 253.5, bullish). These figures imply meaningful upside potential in the long run, but they are estimates, not guarantees.
Tap a question to reveal the answer.
2030 min $0.8355, avg $1.27, max $2.09; ROI 2.3; sentiment NEUTRAL.
Forecast shows neutral sentiment through 2030, then bullish from 2031 onward, with notable upside in later years (e.g., 2031 avg $1.75 ROI 40.8; 2040 avg $3.05 ROI 146.1; 2050 avg $4.38 ROI 253.5). These are estimates, not guarantees.
Yes, the 2030 forecast lists a maximum of $2.09, with an average of $1.27 and a minimum of $0.8355; ROI 2.3; sentiment NEUTRAL.
Current price is $1.24 and market cap is $61.04M.
The 30-day range is $0.9267 to $1.66.
Entera Bio Ltd. Community Discussion
0Share your Entera Bio Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.